KRAS and neoplasm: Second, KRAS-mutant tumors with coexisting TP53 or KEAP1 mutations were associated with a more aggressive tumor phenotype, and loss of KEAP1 in tumors exhibits unique characteristics dictated by their cellular origin and metabolic program [34].